Roquefort Therapeutics Plc (LSE:ROQ) has announced a proposed acquisition of the exclusive worldwide licence to AO-252, a novel precision oncology asset that could significantly expand the company’s pipeline of targeted cancer therapies.
The announcement comes as the company prepares to rebrand as Coil Therapeutics, with Dr Sotirios Stergiopoulos set to assume the role of incoming chairman. The move reflects a strategic focus on innovative oncology assets aimed at addressing major unmet needs in cancer treatment.
Speaking on The Watchlist, Dr Stergiopoulos outlined the scientific rationale behind AO-252 and the potential opportunity it represents within the rapidly evolving precision oncology landscape.
A Novel Target in Precision Oncology
Precision oncology continues to gain momentum across the biotechnology sector as researchers seek treatments tailored to the biological drivers of disease rather than using broad, non-specific therapies.
According to Dr Stergiopoulos, AO-252 represents a particularly differentiated opportunity because it targets a previously underexplored biological mechanism.
The asset is designed to enhance protein–protein interactions, a strategy that can influence several critical pathways involved in cancer progression. Unlike many oncology therapies that focus on a single mechanism, AO-252 appears to operate across multiple biological processes.
These include:
- DNA damage repair pathways
- Mitotic inhibition
- Immune system modulation
Dr Stergiopoulos explained that this multi-mechanism approach may give AO-252 a unique therapeutic profile compared with existing oncology drugs.
Another potentially important feature is the compound’s ability to cross the blood–brain barrier, achieving exposure levels in the brain comparable to those in the rest of the body. This characteristic could allow the therapy to target cancers that metastasise to the brain, a significant clinical challenge in oncology.
Potential Across Multiple Tumour Types
While early development has focused on specific tumour types, the broader therapeutic potential of AO-252 could be substantial.
Initial clinical development began with three key indications:
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial cancer
However, emerging data suggests the therapy may have activity across multiple solid tumours, expanding its possible application.
Dr Stergiopoulos highlighted particular promise in areas such as:
- Ovarian cancer
- Prostate cancer
- Gastric cancer
- Solid tumours that metastasise to the brain
Based on current estimates and comparable therapies in development, the combined market opportunity for these indications could exceed $20 billion, with the potential to grow significantly if the drug proves effective across a broader range of cancers.
He also noted that AO-252’s favourable safety profile could make it suitable for combination therapy, which may further expand its commercial potential within the global oncology market.
Encouraging Early Clinical Signals
AO-252 is currently being evaluated in a Phase 1 clinical trial, designed primarily to determine the optimal dosing strategy through a dose-escalation study.
The trial initially focused on the three original tumour indications but was expanded in October 2025 to include all solid tumours, enabling researchers to gather broader clinical insights.
According to Dr Stergiopoulos, early signals from the study have been encouraging.
In one patient cohort receiving 80 mg twice daily, three out of four patients demonstrated tumour regression signals, translating to a clinical benefit rate of approximately 75%.
Notably:
- One ovarian cancer patient experienced a 30% reduction in tumour size and remained on treatment for eight months.
- An endometrial cancer patient also showed greater than 30% tumour reduction, remaining in the trial for more than four to six months.
Importantly, the therapy has so far shown no significant safety issues, which investigators view as a strong indicator of its potential viability as both a standalone and combination therapy.
Key Milestones Ahead
The ongoing Phase 1 trial continues to focus on identifying the maximum tolerated dose while monitoring early efficacy signals.
As the study progresses, investors and industry observers will be watching closely for:
- Final dose-escalation results
- Expansion cohort data across multiple tumour types
- Additional safety and efficacy readouts
If positive trends continue, AO-252 could represent a significant addition to the oncology pipeline being developed by Roquefort Therapeutics Plc, and a central component of the strategy as the company transitions to its Coil Therapeutics identity.
With precision oncology remaining one of the most dynamic areas of drug development, assets such as AO-252 highlight the growing emphasis on targeted, mechanism-driven therapies designed to improve outcomes for cancer patients worldwide.
For more information on Roquefort Therapeutics visit- https://www.roquefortplc.com/
Leave a Reply